This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 38/9/2491    most recent STROKEAHA.106.480111v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Foerch, C. Articles by Montaner, J. Search for Related Content PubMed PubMed Citation Articles by Foerch, C. Articles by Montaner, J. Related Collections Thrombolysis Other diagnostic testing Acute Cerebral Hemorrhage Acute Cerebral Infarction Emergency treatment of Stroke

(Stroke. 2007;38:2491.)
© 2007 American Heart Association, Inc.

Original Contributions

Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke

Christian Foerch, MD; Michael T. Wunderlich, MT, MD; Florian Dvorak, MD; Marek Humpich, MD; Timo Kahles, MD; Michael Goertler, MD; Jose Alvarez-Sabín, MD; Claus W. Wallesch, MD; Carlos A. Molina, MD; Helmuth Steinmetz, MD; Matthias Sitzer, MD Joan Montaner, MD

From the Department of Neurology (C.F., F.D., M.H., T.K., H.S., M.S.), Johann Wolfgang Goethe University, Frankfurt am Main, Germany; the Department of Neurology (M.T.W., M.G., C.W.W.), Otto von Guericke University, Magdeburg, Germany; and the Neurovascular Research Laboratory, Stroke Unit, Department of Neurology (J.A.-S., C.A.M., J.M.), Vall d’Hebron Hospital, Barcelona, Spain.

Correspondence to Christian Foerch, MD, Department of Neurology, Johann Wolfgang Goethe University, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany. E-mail foerch{at}em.uni-frankfurt.de

Background and Purpose— Intracerebral hemorrhage constitutes an often fatal sequela of thrombolytic therapy in patients with ischemic stroke. Early blood–brain barrier disruption may play an important role, and the astroglial protein S100B is known to indicate blood–brain barrier dysfunction. We investigated whether elevated pretreatment serum S100B levels predict hemorrhagic transformation (HT) in thrombolyzed patients with stroke.

Methods— We retrospectively included 275 patients with ischemic stroke (mean age of 69±13 years; 46% female) who had received thrombolytic therapy within 6 hours of symptom onset. S100B levels were determined from pretreatment blood samples. Follow-up brain scans were obtained 24 hours after admission, and HT was classified as either hemorrhagic infarction (1, 2) or parenchymal hemorrhage (1, 2).

Results— HT occurred in 80 patients (29%; 45 hemorrhagic infarction, 35 parenchymal hemorrhage). Median S100B values were significantly higher in patients with HT (0.14 versus 0.11 µg/L; P=0.017). An S100B value in the highest quintile corresponded to an OR for any HT of 2.87 (95% CI: 1.55 to 5.32; P=0.001) in univariate analysis and of 2.80 (1.40 to 5.62; P=0.004) after adjustment for age, sex, symptom severity, timespan from symptom onset to hospital admission, vascular risk factors, and storage time of serum probes. A pretreatment S100B value above 0.23 µg/L had only a moderate sensitivity (0.46) and specificity (0.82) for predicting severe parenchymal bleeding (parenchymal hemorrhage 2).

Conclusions— Elevated S100B serum levels before thrombolytic therapy constitute an independent risk factor for HT in patients with acute stroke. Unfortunately, the diagnostic accuracy of S100B is too low for it to function in this context as a reliable biomarker in clinical practice.

Key Words: biomarker • blood–brain barrier • intracerebral hemorrhage • S100B • thrombolysis